Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy
Angewandte Chemie International Edition · 11.09.2023 · 62 (37)
DOI: 10.1002/anie.202306863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 03.08.2023. Verfasst von Jingjing Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative Innovation Center of Chin…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions, State Key Laboratory of Analytical Chemistry for Life Science.
Abstract (Originalsprache)
CRISPR system‐assisted immunotherapy is an attractive option in cancer therapy. However, its efficacy is still less than expected due to the limitations in delivering the CRISPR system to target cancer cells. Here, we report a new CRISPR/Cas9 tumor‐targeting delivery strategy based on bioorthogonal reactions for dual‐targeted cancer immunotherapy. First, selective in vivo metabolic labeling of cancer and activation of the cGAS‐STING pathway was achieved simultaneously through tumor microenvironment (TME)‐biodegradable hollow manganese dioxide (H‐MnO 2 ) nano‐platform. Subsequently, CRISPR/Cas9 system‐loaded liposome was accumulated within the modified tumor tissue through in vivo click chemistry, resulting in the loss of protein tyrosine phosphatase N2 (PTPN2) and further sensitizing tumors to immunotherapy. Overall, our strategy provides a modular platform for precise gene editing in vivo and exhibits potent antitumor response by boosting innate and adaptive antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chine…
- College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Xianlin Road 163, Nanjing, 21002…
- School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou, 225002, China.
- Academy of National Food and Strategic Reserves Administration, No. 11 Baiwanzhuang Str, Xicheng District, Beijing, 100037, China.
ORCID-Profile: Yujun Song
Förderung
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- State Key Laboratory of Analytical Chemistry for Life Science
Zitieren
APA
Yang, J., Yang, K., Du, S., Luo, W., Wang, C., Liu, H., Liu, K., Zhang, Z., Gao, Y., Han, X., & Song, Y. (2023). Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy. Angewandte Chemie International Edition, 62(37). https://doi.org/10.1002/anie.202306863
Vancouver
Yang J, Yang K, Du S, Luo W, Wang C, Liu H, et al. Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy. Angewandte Chemie International Edition. 2023;62(37). doi:10.1002/anie.202306863
BibTeX
@article{Yang2023,
author = {Yang, Jingjing and Yang, Kaiyong and Du, Shiyu and Luo, Wen and Wang, Chao and Liu, Hongmei and Liu, Kunguo and Zhang, Zhibin and Gao, Yanfeng and Han, Xin and Song, Yujun},
title = {Bioorthogonal Reaction‐Mediated Tumor‐Selective Delivery of CRISPR/Cas9 System for Dual‐Targeted Cancer Immunotherapy},
journal = {Angewandte Chemie International Edition},
year = {2023},
volume = {62},
number = {37},
doi = {10.1002/anie.202306863}
}
EUVIMED